173 related articles for article (PubMed ID: 23819605)
1. Immunohistochemical analysis of chromatin remodeler DAXX in high grade urothelial carcinoma.
Zizzi A; Montironi MA; Mazzucchelli R; Scarpelli M; Lopez-Beltran A; Cheng L; Paone N; Castellini P; Montironi R
Diagn Pathol; 2013 Jul; 8():111. PubMed ID: 23819605
[TBL] [Abstract][Full Text] [Related]
2. Karyometry and quantitative immunohistochemical analysis of the urothelium in tissue sections: a feasibility study based on chromatin remodeler DAXX immunostaining.
Zizzi A; Montironi MA; Mazzucchelli R; Scarpelli M; Lopez-Beltran A; Cheng L; Di Primio R; Paone N; Castellini P; Montironi R
J Biol Regul Homeost Agents; 2013; 27(3):913-7. PubMed ID: 24152857
[TBL] [Abstract][Full Text] [Related]
3. Global acetylation and methylation changes predict papillary urothelial neoplasia of low malignant potential recurrence: a quantitative analysis.
Mazzucchelli R; Scarpelli M; Lopez-Beltran A; Cheng L; Bartels H; Bartels PH; Alberts DS; Montironi R
Int J Immunopathol Pharmacol; 2011; 24(2):489-97. PubMed ID: 21658323
[TBL] [Abstract][Full Text] [Related]
4. Immunohistochemical evaluation of global DNA methylation and histone acetylation in papillary urothelial neoplasm of low malignant potential.
Barbisan F; Mazzucchelli R; Santinelli A; Stramazzotti D; Scarpelli M; Lopez-Beltran A; Cheng L; Montironi R
Int J Immunopathol Pharmacol; 2008; 21(3):615-23. PubMed ID: 18831929
[TBL] [Abstract][Full Text] [Related]
5. Microtubule-organizing center-mediated structural atypia in low- and high-grade urothelial carcinoma.
Murata SI; Kuroda M; Kawamura N; Warigaya K; Musangile FY; Matsuzaki I; Kojima F
Virchows Arch; 2021 Feb; 478(2):327-334. PubMed ID: 32710188
[TBL] [Abstract][Full Text] [Related]
6. Noninvasive low-grade papillary urothelial carcinoma with degenerative nuclear atypia: a grading pitfall.
Matoso A; Parimi V; Epstein JI
Hum Pathol; 2021 Jul; 113():1-8. PubMed ID: 33887303
[TBL] [Abstract][Full Text] [Related]
7. Recurrent papillary urothelial neoplasm of low malignant potential. Subtle architectural disorder detected by quantitative analysis in DAXX-immunostained tissue sections.
Castellini P; Montironi MA; Zizzi A; Scarpelli M; Mazzucchelli R; Lopez-Beltran A; Cheng L; Paone N; Montironi R
Hum Pathol; 2014 Apr; 45(4):745-52. PubMed ID: 24565208
[TBL] [Abstract][Full Text] [Related]
8. Transition between urothelial carcinoma in situ and non-invasive micropapillary carcinoma as a pivot connection between diverse morphologies of bladder carcinoma: a case report of urothelial carcinoma with villoglandular differentiation.
Tajima S; Koda K
Int J Clin Exp Pathol; 2015; 8(3):3288-93. PubMed ID: 26045854
[TBL] [Abstract][Full Text] [Related]
9. Utility of uroplakin II expression as a marker of urothelial carcinoma.
Tian W; Guner G; Miyamoto H; Cimino-Mathews A; Gonzalez-Roibon N; Argani P; Li X; Sharma R; Subhawong AP; Rezaei K; Bivalacqua TJ; Epstein JI; Bishop JA; Netto GJ
Hum Pathol; 2015 Jan; 46(1):58-64. PubMed ID: 25449628
[TBL] [Abstract][Full Text] [Related]
10. Keratin 17 is a sensitive and specific biomarker of urothelial neoplasia.
Babu S; Mockler DC; Roa-Peña L; Szygalowicz A; Kim NW; Jahanfard S; Gholami SS; Moffitt R; Fitzgerald JP; Escobar-Hoyos LF; Shroyer KR
Mod Pathol; 2019 May; 32(5):717-724. PubMed ID: 30443013
[TBL] [Abstract][Full Text] [Related]
11. Intratumoral heterogeneity of surrogate molecular subtypes in urothelial carcinoma in situ of the urinary bladder: implications for prognostic stratification of high-risk non-muscle-invasive bladder cancer.
Garczyk S; Bischoff F; Schneider U; Golz R; von Rundstedt FC; Knüchel R; Degener S
Virchows Arch; 2021 Aug; 479(2):325-335. PubMed ID: 33650041
[TBL] [Abstract][Full Text] [Related]
12. Distribution and location of Daxx in cervical epithelial cells with high risk human papillomavirus positive.
Tang SY; Li L; Li YL; Liu AY; Yu MJ; Wan YP
Diagn Pathol; 2014 Jan; 9():1. PubMed ID: 24398161
[TBL] [Abstract][Full Text] [Related]
13. p-120 Catenin is a Useful Diagnostic Biomarker for Distinguishing Plasmacytoid and Sarcomatoid Variants From Conventional Urothelial Carcinoma.
Acosta AM; Barletta J; Sonpavde G; Schnitt S; Hirsch MS
Arch Pathol Lab Med; 2021 Aug; 145(8):1000-1008. PubMed ID: 33237989
[TBL] [Abstract][Full Text] [Related]
14. Discriminatory immunohistochemical staining of urothelial carcinoma in situ and non-neoplastic urothelium: an analysis of cytokeratin 20, p53, and CD44 antigens.
McKenney JK; Desai S; Cohen C; Amin MB
Am J Surg Pathol; 2001 Aug; 25(8):1074-8. PubMed ID: 11474293
[TBL] [Abstract][Full Text] [Related]
15. Immunohistochemical staining patterns of Ki-67 and p53 in florid reactive urothelial atypia and urothelial carcinoma in situ demonstrate significant overlap.
Nguyen JK; Przybycin CG; McKenney JK; Magi-Galluzzi C
Hum Pathol; 2020 Apr; 98():81-88. PubMed ID: 32142835
[TBL] [Abstract][Full Text] [Related]
16. Strong immunohistochemical expression of fibroblast growth factor receptor 3, superficial staining pattern of cytokeratin 20, and low proliferative activity define those papillary urothelial neoplasms of low malignant potential that do not recur.
Barbisan F; Santinelli A; Mazzucchelli R; Lopez-Beltran A; Cheng L; Scarpelli M; van der Kwast T; Montironi R
Cancer; 2008 Feb; 112(3):636-44. PubMed ID: 18072261
[TBL] [Abstract][Full Text] [Related]
17. Correlation of Wnt5a expression with histopathological grade/stage in urothelial carcinoma of the bladder.
Malgor R; Crouser S; Greco D; Brockett C; Coschigano K; Nakazawa M; Jenkinson S
Diagn Pathol; 2013 Aug; 8():139. PubMed ID: 23947922
[TBL] [Abstract][Full Text] [Related]
18. WHO 1973 grade 3 and infiltrative growth pattern proved, aberrant E-cadherin expression tends to be of predictive value for progression in a series of stage T1 high-grade bladder cancer after organ-sparing approach.
Otto W; Breyer J; Herdegen S; Eder F; Bertz S; May M; Mayr R; Lausenmeyer EM; Denzinger S; van Rhijn BW; Burger M; Hartmann A
Int Urol Nephrol; 2017 Mar; 49(3):431-437. PubMed ID: 28035618
[TBL] [Abstract][Full Text] [Related]
19. Clinical significance of the reduction of UT-B expression in urothelial carcinoma of the bladder.
Li C; Xue H; Lei Y; Zhu J; Yang B; Gai X
Pathol Res Pract; 2014 Dec; 210(12):799-803. PubMed ID: 25445116
[TBL] [Abstract][Full Text] [Related]
20. GATA3 immunohistochemistry in urothelial carcinoma of the upper urinary tract as a urothelial marker and a prognosticator.
Inoue S; Mizushima T; Fujita K; Meliti A; Ide H; Yamaguchi S; Fushimi H; Netto GJ; Nonomura N; Miyamoto H
Hum Pathol; 2017 Jun; 64():83-90. PubMed ID: 28428106
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
